Connect with us


Innocan’s CBD study shows promising results



A study on mice has demonstrated a prolonged release of CBD into the blood for at least three weeks after one administration.

The findings open the door for future experiments to prove the lack of toxicity and beneficial therapeutic efficacy of CBD.

The study was conducted by The Hebrew University of Jerusalem, Israel, and based on Innocan’s licensed CBD-loaded liposome platform technology for injectable CBD.

It was led by Dr. Ahuva Cern, senior researcher in the lab of Prof. Berenholz, and conducted in The Hebrew University of Jerusalem laboratories on over 35 mice.

It found significant amounts of CBD in the mice’s blood 21 days after they were injected with a single injection of liposomal CBD.

These results are substantial when comparing the oral or smoking administration of CBD, in which CBD was found in the blood of mice only for a period of up to 36 hours after one administration.

Innocan Israel, a wholly owned subsidiary of the company is working with Yissum Research and Development Company, the commercial arm of The Hebrew University of Jerusalem to design, characterise and evaluate hydrogels containing CBD loaded liposomes.

The research and development is led by Professor Chezy Barenholz, head of the Membrane and Liposome research department at The Hebrew University.

He says: ” I believe that the results of this animal study, showing the prolonged release of CBD into the blood stream is an extremely important major milestone.

“This may open a wide range of clinical applications which may allow for the maintenance of a certain level of CBD in the blood for a longer period of time which may also lead to improved patient’s compliance. If successful, this technology may be beneficial for various additional indications.”

Iris Bincovich, Innocan’s CEO, adds: “As variety of studies demonstrates the effectiveness of cannabinoids in the treatment of various CNS conditions, this has the potential to address indication such as Epilepsy.”

Innocan Israel is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD.


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.